Enanta Pharmaceuticals (ENTA) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Sector Update: Health Care Stocks Mixed Tuesday Afternoon
MT NewswiresDec 24 12:47 ET
Top Midday Decliners
MT NewswiresDec 24 12:38 ET
CrowdStrike To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday
BenzingaDec 24 09:49 ET
Enanta Pharmaceuticals to Appeal Court Ruling on Patent Infringement Case Against Pfizer
MT NewswiresDec 24 07:56 ET
Enanta Pharmaceuticals to Appeal Ruling in Patent Infringement Case Against Pfizer
WSJDec 24 07:24 ET
Court Rules Enanta Patent Invalid in Pfizer Paxlovid Case; Appeal Planned
BenzingaDec 24 07:04 ET

Comments

thoughtful Narwhal_3

Dec 9 05:49

$Enanta Pharmaceuticals (ENTA.US)$ topline data looks good

Jaguar8

Dec 9 05:32

NEWS

$Enanta Pharmaceuticals (ENTA.US)$
Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)
• Observed an antiviral effect for the primary and secondary virology endpoints in the overall population, with a viral load decline of 1.4 log at the end of treatment in Part 2
• Demonstrated a viral load decline of 1.2 log compared to placebo at the end of treatment in prespecified ...

1

This_Guy

Dec 9 05:32

$Enanta Pharmaceuticals (ENTA.US)$
Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)
Positive
Achieved primary endpoint with 1.4 log viral load decline at Day 5 in Part 2
Demonstrated favorable safety profile with no treatment discontinuations
Received FDA Fast Track designation
Successfully achieved target drug exposure levels across all age groups
Showed 1.2 log viral loa...

Moomoo AI

Mar 5 20:53

Enanta Pharmaceuticals' P/S ratio remains low despite recent share price jump, likely due to weak revenue forecast. Market sentiment doesn't anticipate a strong share price rise soon.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Fly 27% But Investors Aren't Buying For Growth

1

Moomoo AI

Feb 12 05:23

Analysts hold a pessimistic view on Enanta Pharmaceuticals after its earnings shortfall. The consensus price target dropped significantly, suggesting lower earnings per share are a key indicator for the company's valuation. The company's long-term prospects are deemed more crucial than next year's earnings.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Reported And Analysts Have Been Cutting Their Estimates

ENTA Enanta Pharmaceuticals

Trade Overview

Capital Trend

News

Comments